Read Online Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. - A Malekzadeh Affiliation: Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. a.malekzadeh@vumc.nl; de Groot V; H Beckerman; van Oosten BW; MA Blankenstein; All authors file in ePub Online

Document Type: Article All Authors / Contributors: A Malekzadeh Affiliation: Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. a.malekzadeh@vumc.nl; de Groot V; H Beckerman; van Oosten BW; MA Blankenstein; C Teunissen ISSN:1046-2023 Language Note: English Unique Identifier: 795527121 Awards: Abstract: Pro and anti-inflammatory cytokines are involved in disease onset and pathophysiology of multiple sclerosis, Alzheimer's disease and Parkinson's disease. It is likely that panels of multiple cytokines provide a good reflection of disease status and can be used as biological markers in body fluids. Different multi-plex platforms, Luminex-xMAP and Meso Scale Discovery, are able to detect multiple analytes in the same sample at the same time. In this literature based review, we offer an overview of the multi-plex platforms and compare them with the golden standard ELISA in their ability to accurately and sensitively detect cytokines in cerebrospinal fluid (CSF) and blood (serum/plasma). The detectability and levels of cytokines in multiple sclerosis, Alzheimer's disease and Parkinson's disease are promising but also show discrepancies between studies. The current immuno-assays lack sensitivity for detection of various cytokines that have low concentrations of cytokines in CSF and blood, and therefore technical improvements are needed. With such improvements the use of large panels of cytokines as inflammatory profiles may offer additional value in diagnosis, prognosis and therapeutic response in neurodegenerative diseases.